Open Label Pilot Study of Perampanel for the Treatment of Alcohol Use Disorder
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to test the safety, tolerability, and effectiveness of
the drug Perampanel when used in persons who drink and wish to stop drinking. Perampanel has
been approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures
but has not yet been approved to treat alcohol use disorders. For this reason, it is
considered an investigational drug. Some people in this study will receive Perampanel alone
and some people will receive Perampanel and Disulfiram, this will be determined by the
pharmacy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Virginia Commonwealth University
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)